Litigation Details for BIOMARIN PHARMACEUTICAL INC. v. AUROBINDO PHARMACEUTICALS LTD. (D.N.J. 2022)

BIOMARIN PHARMACEUTICAL INC. v. AUROBINDO PHARMACEUTICALS LTD. (D.N.J. 2022)

Docket		Date Filed	2022-04-22
Court	District Court, D. New Jersey	Date Terminated	2022-06-24
Cause	35:271 Patent Infringement	Assigned To	Michael Andre Shipp
Jury Demand	None	Referred To	Tonianne J. Bongiovanni
Patents	7,566,462; 7,566,714; 7,612,073; 7,727,987; 8,003,126; 8,067,416; 8,318,745; RE43,797
Link to Docket	External link to docket

Details for BIOMARIN PHARMACEUTICAL INC. v. AUROBINDO PHARMACEUTICALS LTD. (D.N.J. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-04-22				External link to document

BIOMARIN v. AUROBINDO (3:22-cv-02345): Litigation Summary, Patent Claims, and Generic Entry Risk for BioMarin’s Therapeutics

Last updated: July 19, 2026

Executive summary:
Case BIOMARIN PHARMACEUTICAL INC. v. AUROBINDO PHARMACEUTICALS LTD. (No. 3:22-cv-02345, filed 2022) is an Orange-Book-driven patent dispute tied to Biomarin’s biologic/specialty portfolio and Aurobindo’s efforts to market a competing product. The litigation posture is typical of Hatch-Waxman/IPR-era patent cases: BiomarIn asserts Orange-Book-listed patents covering one or more drug substance, formulation, or method-of-use aspects, while Aurobindo contests infringement and/or validity, often teeing up a potential Paragraph IV outcome and an FDA marketing/launch timeline downstream. Without the docket’s specific pleading and order record, the precise patents asserted, their expiration dates, and the settlement or trial posture cannot be stated accurately.

What patents are asserted in BIOMARIN PHARMACEUTICAL v. AUROBINDO 3:22-cv-02345?

Answer (docket-dependent): The asserted patent list, asserted claims, and the asserted theory (direct infringement, induced, contributory, or willful infringement) are determined by the complaint and any amended pleadings in 3:22-cv-02345.

What types of Orange-Book patents do cases like this typically assert?

In Orange-Book litigation involving specialty products, asserted patents usually fall into one or more categories:

• Composition/formulation patents (dosage form, excipients, stabilizers, concentration ranges, lyophilized or liquid presentation)
• Method-of-use patents (dosing regimen, patient subset, therapeutic use)
• Manufacturing/process patents (steps that affect stability, purity, viral inactivation, aggregation control)
• Compound/drug substance patents (if the product is tied to a small-molecule or a fixed intermediate)

Which Biomarin assets commonly appear in generic challenge disputes?

Biomarin’s portfolio has historically included products that attract patent litigation on:

• biologics-like products and adjunct formulations
• dosing and administration regimens
• stability and manufacturing controls for long-term shelf-life

However, the specific product and patent IDs for 3:22-cv-02345 are not specified in the prompt, so they cannot be identified here without creating an error.

What is the procedural timeline in BIOMARIN v. AUROBINDO (3:22-cv-02345)?

Answer (docket-dependent): The meaningful timeline elements are:

• Complaint filing date
• Patent(s) identified as Orange-Book-listed
• Service and responsive pleadings
• Claim construction schedule
• Motions practice (e.g., dismissal, summary judgment, non-infringement, invalidity)
• Trial or settlement milestones

Key milestones that drive “when can a generic launch?”

The timeline impacts launch risk through:

• Injunction scope (which patents block launch)
• Validity/infringement outcomes (if litigated)
• Design-around feasibility (if patents cover formulation or method-of-use)
• FDA approval timing in relation to district court judgment

How does this BIOMARIN v. AUROBINDO case affect FDA approval and market entry risk?

Answer (docket-dependent): The market entry risk depends on what Aurobindo filed (typically an Abbreviated New Drug Application, or an ANDA with a Paragraph IV certification) and which patents the court finds valid and infringed.

What outcomes typically determine launch timing in Orange-Book cases

• Settlement: Often includes a defined “skinny label,” entry at a date, or use/design restrictions
• Final judgment: If Aurobindo loses on infringement and validity for the blocking patents, FDA approval and launch can be stayed
• Win for Aurobindo: If the asserted patents are invalid or not infringed, FDA approval may proceed sooner

What Paragraph IV issues are at stake in BIOMARIN v. AUROBINDO (3:22-cv-02345)?

Answer (docket-dependent): Paragraph IV disputes focus on:

• Whether the ANDA’s proposed product infringes the asserted claims
• Whether the asserted patents are invalid under §102, §103, §112, or §101 frameworks
• Whether the certification was appropriate for the Orange-Book listing

Typical invalidity attack points

Courts often confront:

• prior art anticipation/obviousness (102/103)
• enablement and written description (112)
• indefiniteness (112)
• obviousness-type double patenting (OTDP)

Typical infringement defense points

• absence of a required element in the accused product or label
• non-infringing formulation or manufacturing design
• lack of induced/contributory infringement
• non-infringement by proposed dosing or patient selection

How strong is the patent estate for Biomarin in this dispute?

Answer (docket-dependent): Patent strength must be assessed using:

• remaining term/expiration dates of the asserted patents
• claim breadth and the construed claim scope
• prior art landscape and the prosecution history
• whether the asserted claims are formulation/process/method-of-use constrained

What strong patent profiles tend to look like

• Narrow but directly applicable formulation/process features
• Claims that survive typical claim construction disputes
• Expiration that leaves little time for generic substitutes
• Multi-patent “evergreening” around core embodiments

What weak patent profiles tend to look like

• Claim construction that collapses the scope into non-infringement
• Prior art coverage that makes the novelty fragile
• Dependency on functional results without a clear structural basis
• Overbroad method-of-use claims vulnerable to indefiniteness or anticipation

What is the infringement analysis likely to focus on in 3:22-cv-02345?

Answer (docket-dependent): The infringement analysis turns on the accused product and its label. In Orange-Book litigation, infringement is usually organized around:

• claim charts tied to the accused formulation or steps
• proposed labeling and dosing information
• evidence about stability, impurity profile, and process equivalence (if process is asserted)

If formulation patents are asserted

Infringement typically centers on:

• excipient identity and concentration ranges
• stability/stabilizer system
• physical form and concentration targets

If method-of-use patents are asserted

Infringement typically centers on:

• patient population
• dose, schedule, and administration route
• whether the proposed labeling induces the patented conduct

Which companies are challenging Biomarin’s exclusivity in this litigation?

Answer (docket-dependent): The named parties are:

• Plaintiff: BioMarin Pharmaceutical Inc.
• Defendant: Aurobindo Pharmaceuticals Ltd. Whether additional co-defendants, manufacturers, or ANDA sponsors are in the case depends on the complaint.

Why co-defendants matter for licensing and supply risk

Co-defendants can include:

• manufacturing subsidiaries
• licensing partners
• marketing authorization holders

What settlement terms typically follow in BIOMARIN v. AUROBINDO-style disputes?

Answer (docket-dependent): Settlement terms, when they occur, often govern:

• the date of first commercial marketing
• launch carve-outs (certain strengths or package sizes)
• label limitations (skinny label)
• supply restrictions and non-design of a specific embodiment
• mutual covenant not to sue on defined patents

The specific settlement posture for 3:22-cv-02345 cannot be described without the docket order record.

What is the Orange Book status for Biomarin patents implicated here?

Answer (docket-dependent): Orange Book status is patent-by-patent:

• listed patents
• expiry dates
• exclusivity codes (if any)
• FDA approval application identifiers tied to the drug product

Because the prompt does not identify the drug product name(s) and Orange-Book-listed patent numbers tied to 3:22-cv-02345, an accurate Orange Book mapping cannot be produced.

What generic entry risks exist for Aurobindo if it wins or loses?

Answer (docket-dependent):

• If Aurobindo wins: launch risk drops if blocking patents are invalidated or found non-infringed.
• If Biomarin wins: launch risk rises through injunction and continued stay risk as long as blocking patents remain in force.

Launch risk also depends on “design-around” feasibility

Even with a partial win, a generic may:

• switch formulation to avoid formulation claims
• adjust label to avoid method-of-use claims
• rely on a different manufacturing process that avoids process constraints

How does this case compare with other BioMarin vs. generic litigation patterns?

Answer (pattern-level): BioMarin’s litigation with generics typically tracks:

• assertion of multiple patents around formulation/process/regimens
• heavy emphasis on claim construction
• settlement dates aligned with patent expiry and FDA milestones

A claim-by-claim comparison requires the patent list and case record for 3:22-cv-02345, which are not present in the prompt.

Key Takeaways

• 3:22-cv-02345 is a patent dispute between BioMarin Pharmaceutical Inc. and Aurobindo Pharmaceuticals Ltd. driven by Hatch-Waxman-style exclusivity and FDA market entry incentives.
• The litigation’s impact on launch timing depends on the asserted patent list, claim scope, validity/infringement outcomes, and any settlement terms.
• No accurate patent numbers, asserted claims, expiry dates, or procedural outcomes can be stated from the information provided.

FAQs

1. What happens to FDA exclusivity stays when a district court case settles in BioMarin v. Aurobindo?
2. How do method-of-use claim constructions affect “skinny label” launch strategies in Hatch-Waxman cases?
3. What evidence is most persuasive in formulation infringement disputes involving excipients and stabilizers?
4. How do Paragraph IV certifications interact with later amendments to proposed labeling?
5. What typical settlement structures govern partial victories and design-arounds in biologic-adjacent Orange-Book litigation?

---

References

1. Docket No. 3:22-cv-02345, BioMarin Pharmaceutical Inc. v. Aurobindo Pharmaceuticals Ltd.